These three dividend-paying Dow stocks dominate the health care sector and look like incredible values now for growth and ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

In-hospital mortality, 3-year mortality, and significant adverse outcomes were assessed with factors such as cardiogenic ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

WARRINGTON, PA — Windtree Therapeutics, Inc. has announced a new patent application for istaroxime derivatives, aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing ...

This comes in the wake of his shock exit from Man United just five months after the club paid £3million to bring him in from St James’ Park. The sporting director’s exit came as a shock ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...